<DOC>
	<DOCNO>NCT02442492</DOCNO>
	<brief_summary>Early-onset placental intrauterine growth restriction ( EO IUGR ) associate high risk perinatal morbidity mortality . In association reduce circulate placental growth factor ( PlGF ) EO IUGR result abnormal placentation inadequate remodelling maternal uteroplacental artery . There know treatment placental IUGR . Management involve intensive fetal surveillance delivery evidence serious fetal compromise . However , remote term , delivery associate significant perinatal mortality morbidity . Sildenafil vasodilates uteroplacental vessel IUGR-affected pregnancy may represent novel therapy .</brief_summary>
	<brief_title>Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction</brief_title>
	<detailed_description>STRIDER Canada one consortium STRIDER randomise control trial ( RCTs ) design determine whether maternal treatment oral sildenafil citrate improve perinatal outcome pregnancy complicate EO IUGR without increase risk mother . STRIDER Canada design investigator-initiated double-blind , randomise placebo-controlled trial 90 woman diagnosis early-onset intrauterine growth restriction intention-to-treat analysis . 90 Women affect pregnancy recruit randomise receive either sildenafil placebo . Women review participate fetal medicine diagnosis pregnancy affect early-onset IUGR 18+0 27+6 week gestation serum PlGF level less 5th percentile gestational age consider randomisation . In Canadian STRIDER , treatment either sildenafil placebo ( 25 mg 3 time per day ) apply time randomisation delivery , 31+6 week gestation whichever come first . All patient randomly assign one treatment analyse together , regardless whether complete receive treatment , intention treat basis .</detailed_description>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Gestational age 18+0 27+6 week AND EO IUGR , define 1. ultrasound ( U/S ) measurement fetal abdominal circumference ( AC ) &lt; 10th percentile gestational age and/or document reduced fetal growth velocity complicate either prior EO IUGR adverse perinatal outcome abnormal uterine artery waveform index pregnancy ; OR 2 . U/S estimate fetal weight ( EFW ) &lt; 700g AND Serum PlGF &lt; 5th percentile gestational age know fetal aneuploidy know fetal anomaly/syndrome/congenital infection confirm time enrolment decision make terminate pregnancy current cocaine vasoconstrictor use ( e.g . crystal meth ) ( risk acute cardiac event ) contraindication sildenafil therapy , e.g . know significant maternal cardiac disease , leave ventricular outflow tract obstruction , concomitant treatment nitrate previous allergy sildenafil know HIV positive status ( due drugdrug interaction sildenafil antiretrovirals ) receive peripheral alphablockers ( e.g . prazosin ) prior participation STRIDER trial preeclampsia gestational hypertension diagnose</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sildenafil</keyword>
	<keyword>IUGR</keyword>
	<keyword>FGR</keyword>
	<keyword>STRIDER</keyword>
</DOC>